TEVA 8229 TEVA 8229 Pill - yellow capsule-shape, 16mm
Pill with imprint TEVA 8229 TEVA 8229 is Yellow, Capsule-shape and has been identified as Sunitinib Malate 37.5 mg. It is supplied by Teva Pharmaceuticals USA, Inc.
Sunitinib is used in the treatment of renal cell carcinoma; gastrointestinal stromal tumor; pancreatic cancer and belongs to the drug classes multikinase inhibitors, VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Sunitinib 37.5 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for TEVA 8229 TEVA 8229
Sunitinib Malate
- Imprint
- TEVA 8229 TEVA 8229
- Strength
- 37.5 mg
- Color
- Yellow
- Size
- 16.00 mm
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors, VEGF/VEGFR inhibitors
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Teva Pharmaceuticals USA, Inc.
- National Drug Code (NDC)
- 00093-8229
- Inactive Ingredients
-
croscarmellose sodium,
magnesium stearate,
mannitol,
povidone k30,
gelatin,
titanium dioxide,
ferric oxide yellow,
ferrosoferric oxide,
D&C Yellow No. 10 Aluminium Lake,
FD&C Blue No. 1 Aluminium Lake,
FD&C Blue No. 2 Aluminium Lake,
FD&C Red No. 40,
shellac,
propylene glycol
Note: Inactive ingredients may vary.
More about sunitinib
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (35)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.